ADVERTORIAL – Sponsored by Alexion, AstraZeneca Rare Disease

^PrUltomiris^® (ravulizumab) now publicly reimbursed for adult anti-AQP4 antibody-positive NMOSD in Ontario, Quebec, Alberta, Nova Scotia, Saskatchewan, and NIHB

Alexion, AstraZeneca Rare Disease is pleased to announce that as of January 20^th, 2026, ravulizumab (Ultomiris) is now listed on the Ontario Drug Benefit program for the treatment of adult patients with anti-aquaporin 4 (AQP4) antibody-positive neuromyelitis optica spectrum disease (NMOSD). Read More